Silver Book Fact

Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by 5% to 6%.

Black D, Delmas P, Eastell R, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM. 2007; 356(18): 1809-22. http://content.nejm.org/cgi/content/abstract/356/18/1809

Reference

Title
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Publication
NEJM
Publication Date
2007
Authors
Black D, Delmas P, Eastell R, et al
Volume & Issue
Volume 356, Issue 18
Pages
1809-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.